US Patent 8,038,988 (Bimatoprost Hair Growth): Scope, Claim Coverage, and U.S. Patent Landscape
US Patent 8,038,988 is a method-of-use patent focused on using bimatoprost, dosed at low topical concentrations, to increase visible and tactile cosmetic hair attributes. The independent claim is broad by route (eyelid margin) and effect (length, thickness, density, luster, sheen, gloss, glow, shine, patina). Dependent claims narrow by concentration (notably ~0.03% w/w) and frequency (at least once daily), and expand the method to eyebrow and scalp administration, including an alopecia use limitation.
What patents protect bimatoprost eyelash growth in the U.S.?
Quick answer: What US 8,038,988 covers
US 8,038,988 protects U.S. methods that increase eyelash hair attributes by administering bimatoprost to the eyelid margin. It also covers eyebrow and scalp hair growth methods, including an alopecia-labeled condition. Based on the claim set provided, the protection is anchored to:
- The anatomic target: eyelid margin (independent claim), eyebrow, and scalp (dependent claims).
- The cosmetic/physical outcomes: length, thickness, density, luster/sheens/gloss/glow/shine/patina.
- Low-dose topical liquid compositions, with specific concentration ranges and exemplified values.
Typical layering in this patent family space (what usually matters operationally)
In bimatoprost “hair growth” IP estates, protection often clusters into three layers that drive freedom-to-operate (FTO):
- Active method-of-use patents (like US 8,038,988): topical administration to specific anatomic sites to increase hair properties.
- Formulation and composition patents: concentration ranges, vehicle systems, preservatives, solubilizers, pH, and dosing forms (solutions vs gels).
- Device and regimen patents: applicator delivery to eyelid margins, dosing frequency, and patient regimen definitions.
Without additional claims beyond those supplied, the analysis below focuses strictly on the provided claim scope of US 8,038,988 and the enforceable boundaries implied by those claim elements.
How broad are the claims of US 8,038,988?
Claim construction map: elements that define infringement risk
From the provided claims, each method claim includes the following infringement-defining features:
Core (Claim 1)
- A method of increasing one or more enumerated eyelash attributes.
- In a human.
- By administering an effective amount of bimatoprost to the eyelid margin.
Concentration and regimen limits (Claims 2, 3, 10, 11)
- Liquid composition with about 0.03% bimatoprost by weight (Claim 2).
- Administered at least once daily (Claim 3).
- A liquid composition with about 0.001% to about 0.1% bimatoprost by weight (Claim 10).
- Human suffering from eyelash loss (Claim 11).
Scope expansion (Claims 4–9, 12–13)
- Eyebrow hair increases by administering bimatoprost to eyebrow (Claim 4), with same ~0.03% w/w and analogous limitations.
- Scalp hair increases by administering bimatoprost to scalp (Claim 7), with concentration range 0.001% to 0.1% (Claim 8) and ~0.03% w/w (Claim 9).
- Scalp/hair loss due to alopecia (Claim 13), which is a narrower clinical-condition limitation.
What makes Claim 1 meaningfully broad?
Claim 1 is not limited to:
- A particular vehicle other than “administering an effective amount” to the eyelid margin.
- A defined concentration (that limitation appears in dependent claims).
- A required frequency (dependent).
- A particular hair-loss diagnosis beyond “increase” in hair attributes (although Claim 11 adds eyelash loss as a condition in a dependent claim).
That structure typically means a competitor cannot avoid infringement on concentration alone if it practices the Claim 1 method with bimatoprost at any “effective amount” to increase eyelash attributes.
What makes Claim 1 still vulnerable to design-arounds?
Claim 1 is tightly bound to:
- Bimatoprost
- Eyelid margin
- The “increase” outcome in eyelash hair properties
Practical design-arounds usually attempt to change at least one of these elements, such as:
- Targeting a different anatomical location (for example, lashes vs eyelid margin distinctions).
- Using a different prostaglandin analogue or formulation strategy that does not use bimatoprost itself.
- Using a dosing approach that avoids achieving the claimed “increase” attributes (not realistic as a design-around if efficacy is desired).
- Avoiding topical administration to the eyelid margin.
How do the dependent claims narrow the protected scope?
Eyelash-dependent claims: concentration and regimen
- Claim 2: liquid composition with about 0.03% w/w bimatoprost.
- Claim 3: administered to eyelid margin at least once a day.
- Claim 10: liquid composition containing about 0.001% to about 0.1% w/w bimatoprost.
- Claim 11: human suffering from eyelash loss.
Operational implication: if a product uses bimatoprost liquid at or around 0.03% applied at least once daily to the eyelid margin, it potentially matches multiple dependent claims even if it also meets Claim 1.
Eyebrow expansion: parallel coverage
- Claim 4: increase eyebrow hair attributes by administering bimatoprost to eyebrow.
- Claims 5 and 6: ~0.03% w/w; composition is a solution.
Operational implication: eyebrow-specific indications can land directly in dependent claim coverage if the same bimatoprost dose and solution composition are used.
Scalp expansion: concentration band and condition narrowing
- Claim 7: increase scalp hair attributes by administering bimatoprost to scalp.
- Claim 8: liquid composition with about 0.001% to about 0.1% w/w.
- Claim 9: ~0.03% w/w.
- Claim 12: human suffering from hair loss.
- Claim 13: hair loss due to alopecia.
Operational implication: Claim 13 provides a tighter clinical condition hook. If a regimen targets alopecia with scalp bimatoprost in that range, it increases the probability that condition-labeled promotional or labeling statements align with claim language.
What formulations are protected by US 8,038,988?
Are “liquid composition” requirements enforceable for infringement?
Dependent claims explicitly require “liquid composition,” including:
- About 0.03% w/w (Claims 2 and 5 and 9).
- 0.001% to 0.1% w/w (Claims 8 and 10).
- “Solution” (Claim 6).
Even if Claim 1 itself does not require a concentration or “liquid” descriptor, dependent claim enforcement risk is higher for liquid solutions formulated within the cited concentration bands and used in the stated anatomic locations.
Concentration bands: the numeric carve points
US 8,038,988’s numeric specificity centers on:
- ~0.03% w/w as a repeated anchor value.
- 0.001% to 0.1% w/w as a broader band.
A formulation that uses bimatoprost outside that band may still risk Claim 1 if it uses an “effective amount,” but it potentially avoids dependent claims 8 and 10 and reduces the strength of arguments tied to the numeric ranges.
When does US 8,038,988 lose exclusivity?
No timeline can be produced from the information provided. A patent’s expiration in the U.S. requires at least one of the following: filing date and grant date pair for the term formula, the presence of any PTA adjustments, or maintenance status data. Since none is provided here, no exclusivity end date can be stated in a way that is complete and accurate.
What generic entry risks exist for bimatoprost eyelash methods?
The key risk: “method” patents are not avoided by making a different formulation
For method-of-use patents like US 8,038,988, a generic manufacturer can still face exposure even if it sells a different dosage form, as long as the practiced method uses:
- bimatoprost
- the claimed anatomic administration site (eyelid margin for Claim 1)
- to increase the specified eyelash hair properties
Where generic risk tends to concentrate in practice
Risk clusters where a generic label or patient instruction aligns with the claims:
- eyelid margin topical bimatoprost use
- once-daily regimen
- liquid solution formulations using ~0.03% w/w or within 0.001%–0.1% w/w
- promotional claims tied to “length, thickness, density, luster, sheen, gloss, glow, shine, patina” style outcomes (even if marketing language varies)
How strong is the patent estate for bimatoprost hair growth?
Strength indicators from the claim set
Based solely on the provided claims, US 8,038,988 has the following strength characteristics:
-
Independent claim breadth (Claim 1)
It is not limited to a numeric concentration or a daily frequency, which increases the likelihood of covering a range of real-world topical dosing.
-
Outcome-based language
It recites specific cosmetic attributes, which can support enforcement via clinical measurement and marketing claims.
-
Multi-site coverage
It covers eyelash, eyebrow, and scalp contexts, which can be leveraged against multiple indications.
-
Narrower dependent hooks
Dependent claims provide multiple narrower claim targets that align with common formulation and dosing practice: ~0.03% and once-daily.
Strength constraints implied by the wording you provided
- The independent claim is still specific to eyelid margin and bimatoprost.
- The condition-limited claims (eyelash loss, alopecia) reduce applicability if a product avoids or does not claim those patient populations.
What patent litigation affects US 8,038,988?
No litigation status can be produced from the information provided. Litigation history requires case captions, docket details, or at least a known listing of related suits. Without that, a complete and accurate litigation analysis is not possible.
How does US 8,038,988 compare with other bimatoprost hair growth patents?
In-claim comparison: breadth across anatomic targets
Within the patent itself, the claim architecture indicates:
- Eyelashes: broadest independent anchor (Claim 1).
- Eyebrows: dependent expansion (Claim 4).
- Scalp hair: dependent expansion (Claim 7), with numeric band (Claim 8) and condition narrowing (Claim 13).
This internal structure typically means the strongest coverage in enforcement focuses on the eyelash administration practice, then broadens to eyebrow/scalp via dependent claims.
Key Takeaways
- US 8,038,988 protects a method of increasing eyelash hair attributes in humans by administering bimatoprost to the eyelid margin (Claim 1), with no explicit concentration or daily frequency requirement in the independent claim.
- The patent adds multiple dependent layers tied to liquid solutions and concentration ranges centered on ~0.03% w/w and 0.001% to 0.1% w/w.
- The method scope expands to eyebrows and scalp, including an alopecia limitation for scalp hair loss (Claim 13).
- A practical FTO focus for competitors is whether their product and use instructions practice the claimed anatomic administration site and achieve hair attribute increases, and whether their formulation and regimen align with the dependent numeric and dosing limitations.
FAQs
-
Does US 8,038,988 require a specific bimatoprost concentration for infringement under Claim 1?
The independent Claim 1 provided does not specify a concentration; dependent claims do.
-
What concentration band is explicitly claimed for scalp use?
Claims 8 and 10 recite about 0.001% to about 0.1% w/w bimatoprost.
-
Is eyebrow coverage included in US 8,038,988?
Yes, Claim 4 covers administering bimatoprost to the eyebrow to increase the enumerated hair attributes.
-
Which claim ties scalp hair loss to alopecia?
Claim 13 states hair loss due to alopecia.
-
Can a once-daily regimen be avoided to reduce risk?
Dependent Claim 3 requires at least once daily for the eyelid margin method, but Claim 1 remains independent of frequency in the provided claims.
